Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, irinotecan, and temozolomide for relapsed or refractory neuroblastoma
NCT01114555Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2010
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT01114555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01114555.